May 10, 2022 - Portal Instruments has been featured in Fierce Pharma. "Gerresheimer invests in Portal's needle-free drug delivery, teeing Takeda partner up to advance tech", showcases Gerresheimer's agreement with Portal to support the development of the needle-free drug delivery platform.
May 10, 2022 -Yesterday, Fierce Pharma published an article showcasing Gerresheimer's investment into Portal Instruments. The article titled, "Gerresheimer invests in Portal's needle-free drug delivery, teeing Takeda partner up to advance tech", showcases Gerresheimer's agreement with Portal to support the development of the needle-free drug delivery platform.
Read the full article here:
October 29, 2020 - Patrick Anquetil, CEO Portal Instruments, demos Portal’s needle-free injector, shares his perspective on being an entrepreneur and discusses Portal’s opportunities during COVID with Radio Entrepreneurs host Jeffrey Davis.
Today Portal Instruments announced a joint publication with Regeneron on the PRIME needle-free injection platform. The findings provided crucial data on Portal's platform, demonstrating the ability to deliver high-viscosity biologics with volume flexibility and tailored injection depths.
June 30, 2021 - The National Transgender Discrimination Survey Report on Health and Health Care recorded at least 80% of transgender people have either taken gender-affirming hormone therapy (GAHT) or want to take GAHT at some point.¹
Please fill out the details below and we will get back to you shortly.